An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for glioblastoma has reported initial results in the Journal of Clinical Oncology. While none of the three therapeutics tested so far improved overall survival of patients, this adaptive platform trial, the first of its kind in neuro-oncology, has the potential to rapidly and efficiently identify therapies that benefit patients.
The trial, called INSIGhT, is still underway testing additional therapies.
In contrast, INSIGhT uses a shared control arm to test multiple investigational therapies at one time. So far, INSIGhT has tested a control arm of standard therapy against abemaciclib , neratinib , and CC-115 . Once underway, the trial adapts to new information. Dana-Farber statisticians led by Lorenzo Trippa, PhD, continuously apply complex statistics to learn from each patient whether the drug they are receiving is having a likely benefit. The randomization algorithms enables future patients joining the trial to have increased odds of getting the best drug for them personally.
"We can quickly stop pursuing drugs that are not promising and at the same time find the effective drugs and move them into phase three testing," says Wen. In this first readout of the trial, patients taking abemaciclib and neratinib experienced longer progression free survival than those receiving standard therapy or CC-115. None of the therapies extended overall survival.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
'We need to normalise conversations about cancer and life after cancer'Mum-of-three Tracey is on a mission to help improve conversations about cancer after being treated for womb cancer
Read more »
Research team leads adaptive, efficient multi-arm phase 2 clinical trial for glioblastomaAn innovative phase 2 clinical trial led by Dana-Farber Cancer Institute, in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for glioblastoma, has reported initial results in the Journal of Clinical Oncology. While none of the three therapeutics tested so far improved overall survival of patients, this adaptive platform trial, the first of its kind in neuro-oncology, has the potential to rapidly and efficiently identify therapies that benefit patients.
Read more »
Researchers discover possible new treatment for triple-negative breast cancerZachary Schug, Ph.D., assistant professor in the Molecular and Cellular Oncogenesis Program of the Ellen and Ronald Caplan Cancer Center at The Wistar Institute, has published a new paper in the journal Nature Cancer. Schug's paper, titled 'Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer,' demonstrates a double-acting mechanism for fighting a particularly aggressive, difficult-to-treat form of breast cancer. Schug's research shows how silencing a certain gene, ACSS2, may improve existing treatments for patients.
Read more »
New CAR T cell therapy approach minimizes severe side effectsIn recent years, cancer researchers have hailed the arrival of chimeric antigen receptor T cell (CAR T) therapy, which has delivered promising results, transforming the fight against various forms of cancer. The process involves modifying patients' T-cells to target cancer cells, resulting in remarkable success rates for previously intractable forms of cancer.
Read more »
'I was diagnosed with a rare tongue cancer at just 19 years old'Rachel Morton was just 19-years-old when she was diagnosed with a rare tongue cancer.
Read more »
Marina Litvinenko: Agent wanted for my husband's murder should confess before cancer kills himThe widow of the Russian spy reflects on fate catching up with the men wanted for his murder, why Russia is becoming a tinder box for civil war while Putin is politically trapped, and the demise of 'criminally minded' Yevgeny Prigozhin
Read more »